Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. The parasite is mostly transmitted by triatomine insects, also known as "kissing bugs," and can also be transmitted through blood transfusions, organ transplants, and from mother to child during pregnancy or childbirth. For many years, treatment options for Chagas disease were very limited. However, over the past few decades, researchers have made significant progress in developing newer and more effective drugs to treat the disease.
Available Treatment Options
Currently, there are two main drugs approved for Chagas Disease Treatment - benznidazole and nifurtimox. These medications work by attacking the parasite directly and aim to clear the infection completely during the acute and early chronic phases of Chagas disease. Benznidazole was developed in the 1970s and was the first drug available for treatment. It needs to be taken for 60 days for adult treatment. Common side effects can include rashes, peripheral neuropathy, and gastrointestinal issues. Nifurtimox was introduced in the 1980s and also requires a 60-day course. It may cause nausea, vomiting, weight loss and headaches. Both drugs have similar cure rates of around 60-70% in the acute phase. However, efficacy is lower in later chronic stages, with reported cure rates of 30-40%.
Research on New Drugs
Despite being the only two available drugs, benznidazole and nifurtimox have several disadvantages like potential toxicity, limited safety evidence, and variable efficacy depending on disease stage and individual health factors. This has fueled continued research on developing improved treatment options. One promising new drug is EPLBS-1259, which recently completed phase 1 clinical trials. In pre-clinical studies, EPLBS-1259 showed strong anti-parasitic activity against both acute and chronic Trypanosoma cruzi infections with once-daily oral dosing. It was also found to be well-tolerated and showed no drug-related severe adverse events in the initial human trials. Phase 2 and 3 studies are planned to further evaluate its safety and efficacy in comparison to existing drugs. Researchers are also exploring other drugs like fexinidazole, which is already approved for another parasitic disease.
Combination Therapy Approach
Some scientists believe that using drug combinations may help overcome treatment challenges like resistance, toxicity issues and variable response among patients. Studies in animal models found that using EPLBS-1259 along with either benznidazole or nifurtimox helped achieve a synergistic effect, completely clearing the parasite in a higher proportion of cases than single drugs alone. This sparked interest in evaluating combination therapies for Chagas disease. A recent phase 2 clinical trial studied the safety and preliminary efficacy of benznidazole plus nifurtimox administered simultaneously for 60 days in adult chronic Chagas patients. Most participants tolerated the combination well without severe adverse events. Parasite clearance rates were also higher compared to historical data on monotherapies, though larger trials are still needed. Research in this area continues as combination regimens could offer a path to shortening treatment durations and further improving cure rates.
Advancing Diagnostics and Monitoring Tools
In parallel, innovations in diagnostics and risk-stratification methods aim to optimize Chagas disease management. Advanced molecular diagnostic tests now allow more accurate identification of infection stages, timely diagnosis of congenital transmission and screening of blood/tissue donors. Newly developed quantitative PCR methods and parasite DNA detection also help monitor treatment response objectively. Studies applying these tools found that residual detectable parasite loads post-treatment correlated with higher risk of disease progression. This suggests risk stratification based on sensitive monitoring tests could help identify candidates most likely to benefit from extended treatment or retreatment in the future. Integrating diagnostic and disease monitoring advances with newer drug regimens holds promise for achieving personalized precision care of Chagas disease.
Get more insights on Chagas Disease Treatment
Global Chagas Disease Treatment Market: OverviewChagas disease is a health condition caused by protozoan parasite named Trypanosoma cruzi.
This disease is also known as American trypanosomiasis.
The insects are also called as Triatominae or "kissing bugs," which are responsible for the spread of the disease in humans as well as in animals.
In the U.S., chagas disease is considered as one of the NPI (Neglected Parasitic Infection).
Increased number of people living with this disease is driving the growth of the global chagas disease treatment market.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=30458The bifurcation of the global chagas disease treatment market is performed based on three important parameters, namely, treatment, end-user, and region.
Apart from this, the market is expected to witness the entry of new players and development of advanced solutions for the treatment of Chagas disease.In recent years, several players in the chagas disease treatment market are focused on increasing investments in research activities.
Chagas disease treatment market report is of immense importance for better understanding of the market which leads to high business growth.
It highlights public demands, competencies and the constant growth of the working industry, vibrant reporting, or high data protection services while analysing market information.
A lot of hard work has been put together and no stone is left unturned while generating this market research report.
This Chagas disease treatment market report defines a chapter on the global market and allied companies with their profiles, which provides important data pertaining to their insights in terms of finances, product portfolios, investment plans, and marketing and business strategies.Global Chagas disease treatment market is expected to grow at a substantial CAGR in the forecast period of 2019-2026.
Rise in special designation from the regulatory authority and high demand of disease specific novel therapies are the key factors that fueling the market growthChagas disease treatment market report delivers an in depth study with present and upcoming opportunities to clarify the future investment in the market.
The market research also provides information about manufacturers, market competition, cost, market effect factors for the forecast period of 2019-2026.
There's no cure for fibromyalgia, but treatment is available at JPRC Neuro Spine Center.
It provides complete surgical and non-surgical treatment in India.
Chagas Disease Treatment Market Chagas disease is an inflammatory infectious disease caused by parasite protest Trypanosoma cruzi found in the feces of triatomine bug which is also known as kissing bug as they typically bites people on the face as they sleep.
Chagas disease is common in Central America, South America and Mexico.
It causes a brief sudden illness which lasting for longtime.
It can later cause heart and digestives complications, if left untreated.Market DriversLarge scape population movements mostly from ruler urban areas of the world have increased the geographic distribution of the Chagas disease is drive the market growthEmergence of drugs used to treat complications associated with Chagas disease such as heart-related complications and digestive-related complications is boosting the market growthConsumption of uncooked food contaminated with feces is propelling g the market growthHigh demand of disease specific novel treatment can also act as a market driverGet Exclusive Sample Report: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chagas-disease-treatment-market Scope of the Chagas Disease Treatment MarketCurrent and future of Chagas Disease Treatment Market outlook in the developed and emerging marketsThe segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast periodRegions/Countries that are expected to witness the fastest growth rates during the forecast periodThe latest developments, market shares, and strategies that are employed by the major market playersGlobal Chagas Disease Treatment Market By Type (Acute Chagas Disease, Chronic Chagas Disease), Treatment (Antiparasitic Treatment, Symptomatic Treatment), Drugs (Benznidazole, Nifurtimox), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026 Browse Related Report Here:Peripheral Arterial Disease (PAD) MarketMetastatic Solid Tumors MarketSome of the leading key players profiled in this study:Few of the major competitors currently working in the global Chagas disease treatment market are Humanigen, Inc, Savant HWP, Inc, Bayer AG, Eisai Co., Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Collaborations Pharmaceuticals, Inc, Astellas Pharma Inc, Sanofi, Pfizer Inc, Epichem Pty Ltd, DAIICHI SANKYO COMPANY, LIMITED, Insud Pharma group, Novartis AG, Kancera AB, AstraZeneca, Maprimed S.A. and others.
Get Detailed Toc and Charts & Tables @ https://www.databridgemarketresearch.com/toc/?dbmr=global-chagas-disease-treatment-marketKey Pointers Covered in the Chagas Disease Treatment Market Trends and Forecast to 2026Chagas Disease Treatment Market New Sales VolumesChagas Disease Treatment Market Replacement Sales VolumesChagas Disease Treatment Market Installed BaseChagas Disease Treatment Market By BrandsChagas Disease Treatment Market SizeChagas Disease Treatment Market Procedure VolumesChagas Disease Treatment Market Product Price AnalysisChagas Disease Treatment Market Healthcare OutcomesChagas Disease Treatment Market Cost of Care AnalysisChagas Disease Treatment Market Regulatory Framework and ChangesChagas Disease Treatment Market Prices and Reimbursement AnalysisChagas Disease Treatment Market Shares in Different RegionsRecent Developments for Chagas Disease Treatment Market CompetitorsChagas Disease Treatment Market Upcoming ApplicationsChagas Disease Treatment Market Innovators StudyInquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-chagas-disease-treatment-marketAbout Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the marketContact: Data Bridge Market ResearchTel: +1-888-387-2818Email: [email protected]
